Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
Russian Federation
GRNTI 68.41 Ветеринария
Background. A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary. Methods. To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later. Results. There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4 % of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6 % of cats; of hookworms in 30.8 and 24.2 %; and of Capillaria spp. In 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3 % of fluralaner plus moxidectin treated and 96.6 % of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97 % and 99.93 %, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions. Conclusions. This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.
Bravecto Plus, cat, emodepside, field study, fluralaner, hookworms, lungworms, moxidectin, praziquantel, roundworms
1. Mircean V., Titilincu A., Vasile C., Prevalence of endoparasites in household cat (Felis catus) populations from Transylvania (Romania) and association with risk factors, Vet Parasitol., 2010, No. 171, pp. 163-166.
2. Barutzki D., Schaper R., Results of parasitological examinations of faecal samples from cats and dogs in Germany between 2003 and 2010, Parasitol Res., 2011, No. 109, S45-60.
3. Capári B., Hamel D., Visser M., Winter R., Pfister K., Rehbein S., Parasitic infections of domestic cats, Felis catus, in western Hungary, Vet Parasitol., 2013, No. 192, pp. 33-42.
4. Knaus M., Rapti D., Shukullari E., Kusi I., Postoli R., Xhaxhiu D., et al., Characterisation of ecto- and endoparasites in domestic cats from Tirana, Albania, Parasitol Res., 2014, No. 113, pp. 3361-3371.
5. Beugnet F., Bourdeau P., Chalvet-Monfray K., Cozma V., Farkas R., Guillot J., et al., Parasites of domestic owned cats in Europe: co-infestations and risk factors, Parasit Vectors, 2014, No. 25(7), pp. 291.
6. Giannelli A., Capelli G., Joachim A., Hinney B., Losson B., Kirkova Z., et al., Lungworms and gastrointestinal parasites of domestic cats: a European perspective, Int J Parasitol., 2017, No. 47, pp. 517-528.
7. Symeonidou I., Gelasakis A.I., Arsenopoulos K., Angelou A., Beugnet F., Papadopoulos E., Feline gastrointestinal parasitism in Greece: emergent zoonotic species and associated risk factors, Parasit Vectors, 2018, No. 11, pp. 4.
8. European Scientific Counsel Companion Animal Parasites, ESCCAP Guideline 1: Worm control in dogs and cats. 3rd edition. 2017. https://www.esccap.org/. Accessed 30 March, 2018.
9. Raue K., Heuer L., Böhm C., Wolken S., Epe C., Strube C., 10-year parasitological examination results (2003 to 2012) of faecal samples from horses, ruminants, pigs, dogs, cats, rabbits and hedgehogs, Parasitol Res., 2017, No. 116, pp. 3315-3330.
10. Lavan R.P., Tunceli K., Zhang D., Normile D., Armstrong R., Assessment of dog owner adherence to veterinarians' flea and tick prevention recommendations in the United States using a cross-sectional survey, Parasit Vectors, 2017, No. 10, pp. 284.
11. Meadows C., Guerino F., Sun F., A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations, Parasit Vectors, 2017, No. 10, pp. 37.
12. Prichard R., Ménez C., Lespine A., Moxidectin and the avermectins: consanguinity but not identity, Int J Parasitol Drugs Drug Resist., 2012, No. 2, pp. 134-153.
13. Arther R.G., Charles S., Ciszewski D.K., Davis W.L., Settje T.S., Imidacloprid/ moxidectin topical solution for the prevention of heartworm disease and the treatment and control of flea and intestinal nematodes of cats, Vet Parasitol., 2005, No. 133, pp. 219-225.
14. Venco L., Mortarino M., Carro C., Genchi M., Pampurini F., Genchi C., Field efficacy and safety of a combination of moxidectin and imidacloprid for the prevention of feline heartworm (Dirofilaria immitis) infection, Vet Parasitol., 2008, No. 154, pp. 67-70.
15. European Medicines Agency, Committee for Medicinal Products for Veterinary Use. Summary of opinion (initial authorization). 2018. http://www.ema.europa. eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authori sation/veterinary/004440/WC500245923.pdf. Accessed 14 June 2018.
16. Ministry for Primary Industries, ACVM register, authorization 13. September 2017. https://eatsafe.nzfsa.govt.nz/web/public/acvm-register. Accessed 14 June 2018.
17. Rohdich N., Zschiesche E., Wolf O., Loehlein W., Pobel T., Gil M.J., et al., Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infected client-owned cats, Parasit Vectors., 2018 (In Press).
18. Jacobs D.E., Arakawa A., Courtney C.H., Gemmell M.A., McCall J.W., Myers G.H., et al., World Association for the Advancement of Veterinary Parasitology (W.A.A. V.P) guidelines for evaluating the efficacy of anthelmintics for dogs and cats, Vet Parasitol., 1994, No. 52, pp. 179-202.
19. Farrington C.P., Manning G., Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk, Stat Med., 1990, No. 9, pp. 1447-1454.
20. Traversa D., Di Cesare A., Di Giulio E., Castagna G., Schaper R., Braun G., et al., Efficacy and safety of imidacloprid 10%/moxidectin 1% spot-on formulation in the treatment of feline infection by Capillaria aerophila, Parasitol Res., 2012, No. 111, pp. 1793-1798.
21. Di Cesare A., Veronesi F., Capelli G., Deuster K., Schaper R., Basano F.S., et al., Evaluation of the efficacy and safety of an imidacloprid 10% / moxidectin 1% spot-on formulation (Advocate®, Advantage® Multi) in cats naturally infected with Capillaria aerophila, Parasitol Res., 2017, No. 116, pp. 55-64.
22. Krüdewagen E.M., Remer C., Deuster K., Schunack B., Wolken S., Crafford D., et al., Chemical compatibility and safety of imidacloprid/flumethrin collar (Seresto®) concomitantly used with imidacloprid/moxidectin (Advocate®, Advantage® Multi) and emodepside/praziquantel (Profender®) spot-on formulations, Parasitol Res., 2015, No. 114 (Suppl. 1), pp. S55-80.
23. Walther F.M., Allan M.J., Roepke R.K., Safety of concurrent treatment of cats with fluralaner and emodepside-praziquantel, Parasit Vectors, 2016, No. 9, pp. 322.
